Steroid profiling helps various pathologies to be rapidly
diagnosed. Results from analyses investigating steroidogenic
pathways may be used as a tool for uncovering pathology
causations and proposals of new therapeutic approaches. The
purpose of this study was to address still underutilized application
of the advanced GC-MS/MS platform for the multicomponent
quantification of endogenous steroids. We developed and
validated a GC-MS/MS method for the quantification of
58 unconjugated steroids and 42 polar conjugates of steroids
(after hydrolysis) in human blood. The present method was
validated not only for blood of men and non-pregnant women
but also for blood of pregnant women and for mixed umbilical
cord blood. The spectrum of analytes includes common
hormones operating via nuclear receptors as well as other
bioactive substances like immunomodulatory and neuroactive
steroids. Our present results are comparable with those from our
previously published GC-MS method as well as the results of
others. The present method was extended for corticoids and
17α-hydroxylated 5α/β-reduced pregnanes, which are useful for
the investigation of alternative “backdoor” pathway. When
comparing the analytical characteristics of the present and
previous method, the first exhibit by far higher selectivity, and
generally higher sensitivity and better precision particularly for
17α-hydroxysteroids.
Dehydroepiandrosterone may influence thyroid function. Its metabolite, 7-oxo-dehydroepiandrosterone, a precursor of immunomodulatory 7-hydroxylated metabolites and thermogenic agent, belongs to candidates of steroid replacement therapy. The question was addressed whether its application does influence laboratory parameters of thyroid function. 7-Oxo-dehydroepiandrosterone in the form of emulgel, 25 mg/day, was applied transdermally to 21healthy men for 8 consecutive days. Morning blood was collected before the treatment (Day 0, Stage 1), during treatment (Day 5, Stage 2), on the first day after the last administration (Day 9, Stage 3), one week (Day 16, Stage 4), and 9 weeks (Day 72, Stage 5) after treatment termination. The levels of thyrotropin, free thyroxine and triiodothyronine, dehydroepiandrosterone, its sulfate and its 7-hydroxyepimers were measured. The changes were evaluated by analysis of variance and correlation analysis. During treatment a significant rise of 7β-hydroxy-dehydroepiandrosterone was
observed, which persisted 1 week after treatment termination. No changes were observed in dehydroepiandrosterone and its sulfate. Though a slight but significant rise of TSH and of both thyroid hormones occurred during treatment, its levels soon returned to the basal values. It was concluded that treatment of 7-oxo- dehydroepiandrosterone affects the
thyroid parameters only temporarily and that it provides a considerable persistent amount of 7β-hydroxy-dehydroepiandrosterone.